WHO Pharmaceuticals Newsletter
No. 4, 2010
The US FDA has recently uncovered fraudulent Tamiflu sold over the internet, which put many patients at risk for anaphylaxis. Read about this and other alerts in our regular sections, Safety of Medicines and Regulatory Matters.
This June, representatives from the pharmaceutical industry and regulatory authorities gathered in Beijing to discuss pharmaceutical development on paediatric formulations. This event was the fourth workshop organized by the Prequalification of Medicines Programme (PQP), which provided an open forum for information exchange on the development, formulation and manufacturing of paediatric medicines. The discussions covered technical, safety and ethical topics with an overall positive feedback from the participants.
Around the same time, Singapore’s Health Sciences Authority (HAS) hosted the first pharmacovigilance training for ASEAN countries. The 5-day training course was a collaboration with WHO and UMC, and aimed to strengthen pharmacovigilance awareness and capabilities in ASEAN nations and to build future collaborations for medicines safety in the region.